Top ▲

Diabetes mellitus, insulin-dependent; IDDM

Disease ID:1032
Name:Diabetes mellitus, insulin-dependent; IDDM
Associated with:3 targets
1 immuno-relevant ligand
Type 1 diabetes mellitus
Database Links
Disease Ontology: DOID:9744
OMIM: 222100


regulator of G-protein signaling 1
References:  2


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved drug: Delays immune-mediated damage of pancreatic β cells and preserves insulin production in the early stages of T1DM.
Clinical Use: Early clinical evidence indicated a propensity towards preventive efficacy in individuals at risk of developing type 1 diabetes [1]. Approved in 2022 to delay the onset of stage 3 type 1 diabetes. was investigated for anti-inflammatory activity in moderate to severe psoriasis, but injection site reactions lead to termination in this disease. | View clinical data
Bioactivity Comments: Teplizumab's CD3e binding affinity will be similar to that of its parent antibody . | View biological activity


Show »

1. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS et al.. (2019) An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med, 381 (7): 603-613. [PMID:31180194]

2. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C et al.. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med, 359 (26): 2767-77. [PMID:19073967]